Ixekizumab: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 32 patientsc19early.org

Ixekizumab for COVID-19

Serious outcome risk
Ixekizumab
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−50%
Mortality (1)−50%
RCTs (1)−50%
Late (1)−50%
00.511.5+
← Ixekizumab
reduces riskIncreased
risk →
c19early.org
October 2026

Ixekizumab COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Pimenta B.. (RCT)−50%1.50 · 0.29–7.81death3/162/16STRUCK
Late treatment−50%1.50 · 0.29–7.813/162/1650% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.64
All studies−50%1.50 · 0.29–7.813/162/1650% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+
Rotate screen for more detailsIncrease width for more details
← Ixekizumab
reduces riskIxekizumab
increases risk →
c19early.org
October 2026

Ixekizumab COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Pimenta B.. (RCT)−50%1.50 · 0.29–7.813/162/16STRUCK
Late treatment−50%1.50 · 0.29–7.813/162/1650% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.64
All studies−50%1.50 · 0.29–7.813/162/1650% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+
Rotate screen for more detailsIncrease width for more details
← Ixekizumab
reduces riskIxekizumab
increases risk →
c19early.org
October 2026

Ixekizumab COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Pimenta B.. (RCT)−50%1.50 · 0.29–7.81death3/162/16STRUCK
Late treatment−50%1.50 · 0.29–7.813/162/1650% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.64
All studies−50%1.50 · 0.29–7.813/162/1650% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+
Rotate screen for more detailsIncrease width for more details
← Ixekizumab
reduces riskIxekizumab
increases risk →
c19early.org
October 2026

Ixekizumab COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Pimenta B.. (RCT)−50%1.50 · 0.29–7.81death3/162/16STRUCK
Late treatment−50%1.50 · 0.29–7.813/162/1650% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.64
All studies−50%1.50 · 0.29–7.813/162/1650% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+
Rotate screen for more detailsIncrease width for more details
← Ixekizumab
reduces riskIxekizumab
increases risk →
c19early.org
October 2026

Ixekizumab COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Pimenta B.. (RCT)−50%1.50 · 0.29–7.813/162/16STRUCK
Late treatment−50%1.50 · 0.29–7.813/162/1650% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.64
All studies−50%1.50 · 0.29–7.813/162/1650% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+
Rotate screen for more detailsIncrease width for more details
← Ixekizumab
reduces riskIxekizumab
increases risk →
c19early.org
October 2026

Ixekizumab COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Pimenta B.. (RCT)−50%1.50 · 0.29–7.81death3/162/16STRUCK
Late treatment−50%1.50 · 0.29–7.813/162/1650% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.64
All studies−50%1.50 · 0.29–7.813/162/1650% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+
Rotate screen for more detailsIncrease width for more details
← Ixekizumab
reduces riskIxekizumab
increases risk →